GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (FRA:A1P0) » Definitions » Cyclically Adjusted Book per Share

Acasti Pharma (FRA:A1P0) Cyclically Adjusted Book per Share : €47.38 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Acasti Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Acasti Pharma's adjusted book value per share for the three months ended in Dec. 2023 was €6.310. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €47.38 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Acasti Pharma's average Cyclically Adjusted Book Growth Rate was -8.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Acasti Pharma was 5.70% per year. The lowest was 3.60% per year. And the median was 4.65% per year.

As of today (2024-05-17), Acasti Pharma's current stock price is €2.44. Acasti Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €47.38. Acasti Pharma's Cyclically Adjusted PB Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Acasti Pharma was 0.95. The lowest was 0.03. And the median was 0.09.


Acasti Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Acasti Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma Cyclically Adjusted Book per Share Chart

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.32 50.37 43.64 50.86 46.57

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.89 46.57 52.38 58.29 47.38

Competitive Comparison of Acasti Pharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Acasti Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acasti Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's Cyclically Adjusted PB Ratio falls into.



Acasti Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Acasti Pharma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=6.31/125.0724*125.0724
=6.310

Current CPI (Dec. 2023) = 125.0724.

Acasti Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201311 80.365 97.182 103.429
201402 99.270 98.051 126.627
201405 107.427 99.394 135.180
201408 100.113 99.315 126.077
201411 111.903 99.078 141.262
201502 105.692 99.078 133.421
201505 105.019 100.263 131.005
201508 95.192 100.579 118.373
201511 91.108 100.421 113.473
201602 81.185 100.421 101.114
201605 73.289 101.765 90.075
201608 67.204 101.686 82.660
201611 61.124 101.607 75.241
201706 42.372 103.029 51.438
201709 32.616 103.345 39.473
201712 19.799 103.345 23.962
201803 9.668 105.004 11.516
201806 6.431 105.557 7.620
201809 -12.868 105.636 -15.236
201812 12.142 105.399 14.408
201903 6.005 106.979 7.021
201906 1.460 107.690 1.696
201909 -0.645 107.611 -0.750
201912 -2.324 107.769 -2.697
202003 6.257 107.927 7.251
202006 5.086 108.401 5.868
202009 3.733 108.164 4.317
202012 6.501 108.559 7.490
202103 10.770 110.298 12.213
202106 10.221 111.720 11.443
202109 13.151 112.905 14.568
202112 13.316 113.774 14.638
202203 13.319 117.646 14.160
202206 13.318 120.806 13.788
202209 13.606 120.648 14.105
202212 12.280 120.964 12.697
202303 8.536 122.702 8.701
202306 7.946 124.203 8.002
202309 6.654 125.230 6.646
202312 6.310 125.072 6.310

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Acasti Pharma  (FRA:A1P0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Acasti Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.44/47.38
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Acasti Pharma was 0.95. The lowest was 0.03. And the median was 0.09.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Acasti Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Acasti Pharma (FRA:A1P0) Business Description

Industry
Traded in Other Exchanges
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

Acasti Pharma (FRA:A1P0) Headlines

No Headlines